ProMIS Neurosciences (PMN)

• Market cap: $30.1M
• 1 day: 1.88%
• 5 days: -2.13%
• 1 month: -7.74%
• 3 months: -25.20%
• 6 months: -40.65%
• Year to date: -33.81%
• 1 year: -20.00%
• 5 years: -90.05%
• 10 years: -90.05%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

Employees: 7

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

400% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 1

158% more capital invested

Capital invested by funds: $4.9M [Q2] → $12.6M (+$7.75M) [Q3]

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

19% more funds holding

Funds holding: 16 [Q2] → 19 (+3) [Q3]

16.64% more ownership

Funds ownership: 17.21% [Q2] → 33.85% (+16.64%) [Q3]